Abstract:Background: Recepteur d'origine nantais (RON) is a receptor tyrosine kinase that is activated by a serum-derived, macrophage stimulating protein (MSP) growth factor and is expressed in many malignant tumors. The aim of the present study was to reveal the protein expression profile of RON and its relationship with clinicopathological characteristics of gastric carcinoma and prognosis.Methods: Gastric carcinoma tissue from 98 patients, along with 29 specimens of paraneoplastic tissue and 10 specimens of normal gastric mucosa, were examined by immunohistochemistry (IHC). Western blot analysis of 19 samples of gastric carcinoma tissue and corresponding paraneoplastic tissue, 8 specimens of normal gastric mucosa, and 2 specimens of normal lymph node samples also detected expression of a splice variant of RON, RON Delta 165. All samples obtained were accompanied by patient follow-up data that ranged from 3 to 89 months (median time: 22 months).Results: The rate of positive RON expression differed significantly between gastric carcinoma tissues [56.1%, (55/98)] and paraneoplastic tissues [25.6%, (8/29)] (p = 0.007). In contrast, RON expression was absent in normal gastric mucosa samples. RON expression positively correlated with the invasive depth of the tumor (p = 0.019), perigastric lymph nodes metastasis (p = 0.019), and TNM stage (p = 0.001). However, RON expression was independent of tumor growth pattern according to Bormann criteria (p = 0.209), histopathological grade (p = 0.196), and incidence of distant metastasis (p = 0.400). RON expression was not related to a patient's survival rate (p = 0.195). RON Delta 165 was strongly expressed in fresh gastric carcinoma tissue, corresponding paraneoplastic tissue, and perigastric lymph nodes with metastatic carcinoma. In contrast, expression of RON Delta 165 was not observed in normal gastric mucosa and normal lymph node tissue samples.Conclusion: RON expression is significant in gastric carcinoma tissue and corresponding paraneoplastic tissue, but is not expressed in normal gastric mucosa. Expression of RON Delta 165 was similarly observed in gastric carcinoma tissue and in metastases present in lymph node tissues. We hypothesize that RON and its splice variant play an important role in the occurrence, progression, and metastasis of gastric carcinoma, and therefore may represent a useful marker to evaluate the biological activity of gastric carcinoma.

RON in hepatobiliary and pancreatic cancers: Pathogenesis and potential therapeutic targets

RON receptor tyrosine kinase in pancreatic ductal adenocarcinoma: Pathogenic mechanism in malignancy and pharmaceutical target for therapy

Potential Therapeutics Specific to C-Met/ron Receptor Tyrosine Kinases for Molecular Targeting in Cancer Therapy.

Pathogenesis Of Ron Receptor Tyrosine Kinase In Cancer Cells: Activation Mechanism, Functional Crosstalk, And Signaling Addiction

Targeting RON receptor tyrosine kinase for treatment of advanced solid cancers: antibody-drug conjugates as lead drug candidates for clinical trials.

Oncogenesis of RON Receptor Tyrosine Kinase： a Molecular Target for Malignant Epithelial Cancers

Targeting RON Receptor Tyrosine Kinase for Treatment of Advanced Solid Cancers: Antibody–drug Conjugates As Lead Drug Candidates for Clinical Trials

RON Mediates Tumor-Promoting Effects in Endometrial Adenocarcinoma

Targeted expression of the receptor tyrosine kinase RON in distal lung epithelial cells results in multiple tumor formation: oncogenic potential of RON in vivo

MSP–RON signalling in cancer: pathogenesis and therapeutic potential

Aberrant RON and MET Co-overexpression As Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer.

Expression of the RON Receptor Tyrosine Kinase and Its Association with Gastric Carcinoma Versus Normal Gastric Tissues.

Receptor tyrosine kinase RON in the pathogenic progression of human bronchioloalveolar carcinoma

Overexpression and Activation of the RON Receptor Tyrosine Kinase in a Panel of Human Colorectal Carcinoma Cell Lines.

Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: generation of different splicing RON variants and their oncogenic potential

Therapeutic Evaluation of Monoclonal Antibody-Maytansinoid Conjugate As a Model of RON-targeted Drug Delivery for Pancreatic Cancer Treatment.

Preclinical Efficacy of Anti-RON Antibody-Drug Conjugate Zt/g4-MMAE for Targeted Therapy of Pancreatic Cancer Overexpressing RON Receptor Tyrosine Kinase.

Multiple variants of the RON receptor tyrosine kinase: biochemical properties, tumorigenic activities, and potential drug targets.

Receptor tyrosine kinase RON and tumor

Oncogenic Variant RON160 Expression in Breast Cancer and Its Potential As a Therapeutic Target by Small Molecule Tyrosine Kinase Inhibitor.

Altered expression of the RON receptor tyrosine kinase in various epithelial cancers and its contribution to tumourigenic phenotypes in thyroid cancer cells.